SAN DIEGO – (COMMERCIAL THREAD) –Robbins Geller Rudman & Dowd LLP announces that buyers of securities of Athira Pharma, Inc. (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 inclusive (the “Class Action Period”) have until August 24, 2021 to solicit an appointment in as the principal applicant in the Athira Pharma class action lawsuit. the Athira Pharma The class action accuses Athira Pharma and its CEO of violations of the Securities Exchange Act of 1934. Athira Pharma class action (Wang v. Athira Pharma, Inc., # 21-cv-00861) began June 25, 2021 in the Western District of Washington and is assigned to Judge Thomas S. Zilly. Two similar pursuits – Jawandha v. Athira Pharma, Inc., n ° 21-cv-00862, and Slyne v. Athira Pharma, Inc., No. 21-cv-00864 – are also pending in the Western District of Washington.
If you have suffered substantial losses and wish to be the primary claimant of the Athira Pharma class action lawsuit, please provide your information by clicking here. You can also contact Robbins Geller’s lawyer JC Sanchez by calling 800 / 449-4900 or emailing [email protected] The principal applicant’s requests for the Athira Pharma The class action must be filed with the court no later than August 24, 2021.
CASE ALLEGATIONS: The Athira Pharma The Class Action alleges that, throughout the Class Period, the Defendants made false and misleading statements and failed to disclose that: (i) research conducted by the President and CEO of Athira Pharma, defendant Leen Kawas, who formed the basis of Athira Pharma’s product candidates and intellectual property, was tainted by Kawas’ scientific misconduct, including manipulation of key data; and (ii) accordingly, the positive statements by the defendants about the activities, operations and prospects of Athira Pharma were materially misleading and omitted material facts necessary to ensure that the statements made were not misleading.
On June 17, 2021, Athira Pharma issued a press release announcing that the board of directors of Athira Pharma had placed Kawas on temporary leave pending a review of actions arising from the doctoral research conducted by Kawas while ‘he was at Washington State University. An article published in STAT News Later that day, it was revealed that the Kawas investigation involved claims that she altered images in four separate articles relating to her research into hepatocyte growth factor (HGF), a protein that may treat Alzheimer’s disease and other neurological disorders. The article noted that although Athira Pharma “has since switched to a different molecule than the one Kawas was working on, it is still aiming to target HGF. Thus, Kawas’ doctoral work laid the biological foundation that Athira continues to use in her approach to the treatment of Alzheimer’s disease. At this news, the Athira Pharma share price fell almost 39%, hurting investors.
THE MAIN COMPLAINANT PROCESS: The Private Securities Litigation Reform Act of 1995 allows any investor who purchased securities of Athira Pharma during the Recourse Period to seek appointment as principal plaintiff in the Athira Pharma class action lawsuit. A principal plaintiff is generally the plaintiff with the greatest financial interest in the remedy sought by the putative class which is also typical and adequate of the putative class. A lead applicant acts on behalf of all other class members by ordering Athira Pharma class action lawsuit. The lead plaintiff can choose a law firm of their choice to argue the case. Athira Pharma class action lawsuit. The ability of an investor to participate in any potential future recovery of the Athira Pharma the class action does not depend on the function of principal plaintiff.
ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 attorneys in 9 offices across the country, Robbins Geller Rudman & Dowd LLP is the largest US law firm representing investors in securities class actions. Robbins Geller lawyers have secured many of the largest shareholder recoveries in history, including the largest securities class action recovery ever – $ 7.2 billion – in In re Enron Corp. Dry. Litigation. The 2020 ISS Securities Class Action Services Top 50 report ranked Robbins Geller # 1 for recovering $ 1.6 billion from investors last year, more than double the amount recovered by any other company from securities claimants. Please visit https://www.rgrdlaw.com/firm.html for more information.
Past results do not guarantee future results.
Services can be performed by lawyers in one of our offices.